evipedia.ai
← Back

Zeaxanthin for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Zeaxanthin, a yellow plant pigment sold as an eye-health dietary supplement, collects in the center of the retina. It reliably builds up there, but that has not been shown to prevent disease. Support is strongest for people at risk of advanced macular degeneration, a leading cause of vision loss in later life; large studies with the related pigment lutein found no effect on thinking skills or survival. Harms appear rare. (Full Review)

Protocol

Lutein-dominant regimen (AREDS2)
10 mg lutein plus 2 mg zeaxanthin daily
Usually within the AREDS vitamin-and-zinc formula
Zeaxanthin-dominant regimen
8 mg/day to 20 mg/day
Once daily suffices given the long half-life
Time of day
Typically with the day's largest fat-containing meal
No time-of-day effect is known
Time to effect
Macular degeneration outcomes
Years
AREDS2 participants were followed for 10 years
Processing speed
4 months
Zeaxanthin-containing supplements sped visual processing
Macular pigment
3–12 months
Combined doses of 20 mg/day or more raised it most

Benefits

Contraindications
  • People with existing foveal crystal deposits
  • Current or former smokers planning more than 4 years of single high-dose carotenoid supplements
  • People allergic to marigold or other daisy-family plants, for marigold-derived products
    •
Key Interactions
  • Plant sterols and stanols (fortified spreads, supplements)
  • Olestra
  • Extended-release niacin and fenofibrate
  • Statins (simvastatin tested)
  • Lutein at equal dose
  • Lutein and meso-zeaxanthin supplements (additive effect)
  • Bile acid sequestrants (colestipol)
    •
Theoretical (inferred from mechanism)
  • Mineral oil laxatives
  • Immune checkpoint inhibitors (pembrolizumab)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Lung Cancer, Crystalline Maculopathy
    •
  • Speculative: Reduced Uptake When Paired With Equal-Dose Lutein, Unknown Safety Above 20 mg/day
    •

Monitoring

Marker Target Why
Macular pigment optical density (MPOD) No established target; rise from own baseline Retinal uptake
Serum or plasma zeaxanthin No established target; rise from own baseline Absorption, adherence
Skin carotenoid score No established target; rise from own baseline Whole-body carotenoid status
Best-corrected visual acuity 20/20 (0.0 logMAR) or better Expected to change in macular degeneration
Dilated retinal examination or OCT No established target; no new foveal crystals or drusen progression Safety check

Cadence: Baseline before starting; macular pigment, skin carotenoid score or serum zeaxanthin at 3–6 months, then every 12 months; retinal examination every 12 months, or every 6 months with intermediate macular degeneration or doses above 10 mg/day

Qualitative Assessment

  • Glare tolerance and recovery after bright light, such as oncoming headlights
  • Comfort and contrast when driving or reading in dim light
  • Eye strain and dryness during long screen sessions
  • Straightness of lines on an Amsler grid
  • Perceived mental focus and stress levels
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.